References of "GENNIGENS, Christine"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailRetifanlimab (INCMGA00012) in Patients With Recurrent MSI-H or dMMR Endometrial Cancer: Results From the POD1UM-101 Study
Berton, Dominique; Pautier, Patricia; Lorusso, Domenica et al

Poster (2021, November 10)

Detailed reference viewed: 29 (1 ULiège)
Full Text
Peer Reviewed
See detailRandomised phase II BGOG/ENGOT-CX1 study of Paclitaxel-Carboplatin with or without Nintedanib in first-line recurrent or advanced cervical cancer
Vergote, IB; Van Nieuwenhuysen, E; Casado, A et al

Conference (2021, October 12)

Detailed reference viewed: 24 (2 ULiège)
Full Text
Peer Reviewed
See detailTisotumab Vedotin + Carboplatin in First-Line or + Pembrolizumab in Previously Treated Recurrent/Metastatic Cervical Cancer: Interim Results of ENGOT-Cx8/GOG-3024/innovaTV 205
Vergote, I.B.; Monk, B.J.; O'Cearbhaill, R.E. et al

Poster (2021, September 19)

Detailed reference viewed: 38 (3 ULiège)
Full Text
Peer Reviewed
See detailOncological patients' reactions to COVID-19 pandemic: A single institution prospective study.
ONESTI, Concetta Elisa ULiege; Schroeder, Hélène ULiege; Rorive, Andrée ULiege et al

in Cancer Reports (2021)

BACKGROUND: The spread of the COVID-19 pandemic has led to a rapid reorganization in all human and hospital activities, with impact on cancer patients. AIM: An analysis of cancer patients fears, and ... [more ▼]

BACKGROUND: The spread of the COVID-19 pandemic has led to a rapid reorganization in all human and hospital activities, with impact on cancer patients. AIM: An analysis of cancer patients fears, and awareness of COVID-19 has been done in this study. METHODS AND RESULTS: We analyzed cancer patients' reactions to the pandemic and their perception of oncological care reorganization, through a 12-item survey, proposed at the peak of pandemic and 3 months later. Overall, 237 patients were included in the study. During the peak of pandemic 34.6% of patients were more worried about COVID-19 than cancer versus 26.4% in the post-acute phase (p = .013). Although 49.8% of patients in the acute phase and 42.3% in the post-acute phase considered their risk of death if infected ≥50%, and more than 70% of patients thought to be at higher risk of complications, the majority of them did not consider the possibility to stop or delay their treatment. Patients were more interested in following news about COVID-19 than cancer and they complied with all preventive measures in more than 90% of the cases. CONCLUSIONS: Although cancer patients worried about COVID-19 and evaluated the risk of complication or death due to COVID-19 as extremely high, they were still asking for the best oncological treatment. [less ▲]

Detailed reference viewed: 46 (12 ULiège)
Full Text
Peer Reviewed
See detailStandard of care in 2021 for patients with ovarian cancer in Belgium
Vergote, I.; Denys, H.; De Grève, J. et al

in Belgian Journal of Medical Oncology (2021), 15(6), 286-91

Detailed reference viewed: 30 (2 ULiège)
Full Text
Peer Reviewed
See detailCancer du col utérin localement avancé : approche multidisciplinaire.
LAPAILLE, Louis ULiege; DE CUYPERE, Marjolein ULiege; GOFFIN, Frédéric ULiege et al

in Revue medicale de Liege (2021), 76(5-6), 507-514

Cervical cancer is the fourth most common cancer in women and is linked in over 95 % of cases to papillomavirus infection, the incidence of which has fallen in recent years due to screening and ... [more ▼]

Cervical cancer is the fourth most common cancer in women and is linked in over 95 % of cases to papillomavirus infection, the incidence of which has fallen in recent years due to screening and vaccination. Almost half of these cancers are diagnosed at a locally advanced stage with an overall 5-year survival of around 65 %. In recent decades, the management strategy of these locally advanced cancers has changed considerably and has allowed the improvement of survival but above all of local control as well as the reduction of toxicity, due to the implementation of imaging. Standard treatment consists of external beam radiation therapy combined with concomitant chemotherapy followed by intrauterine brachytherapy. The role of neo-adjuvant and adjuvant chemotherapy is still being evaluated. New therapeutic approaches (particularly immunotherapy) in addition to standard treatment are also being studied. [less ▲]

Detailed reference viewed: 76 (2 ULiège)
Full Text
Peer Reviewed
See detailOptimal treatment in locally advanced cervical cancer.
GENNIGENS, Christine ULiege; DE CUYPERE, Marjolein ULiege; HERMESSE, Johanne ULiege et al

in Expert review of anticancer therapy (2021)

INTRODUCTION: Locally advanced cervical cancer (LACC) (International Federation of Gynecology and Obstetrics (FIGO) 2009/2018 - stages IB2-IVA/IB3-IVA, respectively) is treated using a multimodal approach ... [more ▼]

INTRODUCTION: Locally advanced cervical cancer (LACC) (International Federation of Gynecology and Obstetrics (FIGO) 2009/2018 - stages IB2-IVA/IB3-IVA, respectively) is treated using a multimodal approach that includes chemoradiotherapy followed by brachytherapy. AREAS COVERED: This review provides an overview of the progress made over the past decade in the treatment of LACC. Prognostic factors, FIGO classification and the role of imaging staging will be discussed. Efficacy of external-beam radiotherapy, brachytherapy and chemotherapy will be detailed. Indications for paraaortic staging lymphadenectomy and adjuvant hysterectomy, as well as follow-up and special population, will be covered. EXPERT OPINION: The initial workup is one of the most crucial steps in the optimal care of patients, which should be realized by a multi-disciplinary expert team. With the implementation of modern conformal radiotherapy techniques, the local control rate has been optimized. Nevertheless, 40% of patients experience recurrence with distant metastasis and a dismal prognosis. Currently, a clear benefit of neo- and adjuvant chemotherapy has not been established. The future likely involves (1) improved selection of patients for whom treatment intensification is justified, (2) a combination of new drugs with chemoradiation that are currently being tested in trials, and (3) the development of tailored treatment based on molecular characteristics. [less ▲]

Detailed reference viewed: 115 (8 ULiège)
Full Text
Peer Reviewed
See detailRecurrent cardiac intimal sarcoma misdiagnosed as a myxoma or malignant transformation of a cardiac myxoma?
Durieux, Rodolphe ULiege; Tchana-Sato, Vincent ULiege; LAVIGNE, Jean-Paul ULiege et al

in Journal of cardiac surgery (2021), 36(1), 357-362

Cardiac intimal sarcoma is extremely rare and aggressive primary malignant cardiac tumors. Here, we reported the case of a young man initially operated for a tumor of the left atrium, causing a dynamic ... [more ▼]

Cardiac intimal sarcoma is extremely rare and aggressive primary malignant cardiac tumors. Here, we reported the case of a young man initially operated for a tumor of the left atrium, causing a dynamic obstruction of the mitral valve and (mis-)diagnosed as a myxoma at the histopathological analysis. Patient presented a local recurrence at 3 months and was reoperated. Pathology revealed this time the presence of an intimal sarcoma. Patient received adjuvant chemotherapy. Despite a good local control, the 1-year follow-up positron emission tomography scan revealed the presence of a metastasis in the left adrenal gland that was surgically resected. This article aims to highlight the risk of misdiagnosis in case of cardiac tumors, the hypothetical concept of malignant transformation of a cardiac myxoma, the aggressive course of the extremely rare cardiac intimal sarcoma, and the therapeutic modalities available to treat this pathology. [less ▲]

Detailed reference viewed: 58 (9 ULiège)
Full Text
Peer Reviewed
See detailPhase Ib/II trial of tisotumab vedotin+/- bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024)
Vergote, Ignace; Concin, Nicole; Mirza Raza, Mansoor et al

Poster (2020, May)

Detailed reference viewed: 56 (3 ULiège)
Full Text
Peer Reviewed
See detailAn update on the management of metastatic clear-cell renal cell carcinoma: the BSMO expert panel recommendations
Delafontaine, B; De Backer, C; Beuselinck, B et al

in Belgian Journal of Medical Oncology (2020), 14(2),

Detailed reference viewed: 42 (2 ULiège)
Full Text
Peer Reviewed
See detailLocally advanced cervical cancer : a descriptive analysis of 20 patients with a visceral recurrence
Verjans, Juline ULiege; KRIDELKA, Frédéric ULiege; DE CUYPERE, Marjolein ULiege et al

in European Gynecology and Obstetrics (2020), 2(4), 255-261

Detailed reference viewed: 38 (4 ULiège)
Full Text
Peer Reviewed
See detailTumor total lesion glycolysis and number of positive pelvic lymph nodes on pretreatment positron emission tomography/computed tomography (PET/CT) predict survival in patients with locally advanced cervical cancer.
DE CUYPERE, Marjolein ULiege; Lovinfosse, Pierre ULiege; Gennigens, Christine ULiege et al

in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020), 0

OBJECTIVE: The aim of this study was to investigate the prognostic value of metabolic parameters obtained at pretreatment [(18)F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ... [more ▼]

OBJECTIVE: The aim of this study was to investigate the prognostic value of metabolic parameters obtained at pretreatment [(18)F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography ([(18)F]FDG PET/CT) in patients with locally advanced cervical cancer. We hypothesize that these metabolic parameters could optimize the treatment decision and thus favor the outcome of patients suffering locally advanced cervical cancer. METHODS: Patients with locally advanced cervical cancer underwent pretreatment PET/CT. Standard uptake values (maximum, mean, peak), metabolic tumor volume, and total lesion glycolysis were measured in the tumor and in the hypermetabolic pelvic lymph nodes. The relationship between clinical, pathological, and PET/CT metabolic parameters with recurrence-free survival and overall survival was assessed by Cox regression analysis. RESULTS: 115 patients with a median age of 52 years (range 23-77) presented with locally advanced cervical cancer. After a mean follow-up of 33.0 months after initiation of therapy, 26 patients (22.6%) recurred of which 17 patients had distant metastasis; 18 (15.7%) patients died. Recurrence-free survival at 2 and 5 years was 79.2% and 72.2%, respectively. The total lesion glycolysis of the tumor and the delay between diagnosis and treatment were significantly associated with recurrence-free survival in the multivariate analysis (HR 1.00, p=0.004, and HR 2.04, p=0.02, respectively). Only the total lesion glycolysis of the tumor ≥373.54 (HR 2.49, 95% CI 1.15 to 5.38; p=0.02) remained significant after log rank testing. Overall survival at 2 and 5 years was 91.7% and 68.8%, respectively. The number of PET-positive pelvic lymph nodes was the only independent prognostic factor for overall survival in the multivariate analysis (HR 1.43, 95% CI 1.13 to 1.81; p=0.003). CONCLUSION: Tumor total lesion glycolysis and the number of positive pelvic lymph nodes on pretreatment PET/CT appear to be independent prognostic factors for recurrence and survival in patients with locally advanced cervical cancer. This may help to select patients who may benefit from therapeutic optimization and closer surveillance. [less ▲]

Detailed reference viewed: 46 (17 ULiège)
Full Text
Peer Reviewed
See detailCorrelation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy.
Gennigens, Christine ULiege; DE CUYPERE, Marjolein ULiege; SEIDEL, Laurence ULiege et al

in Cancer Medicine (2020)

BACKGROUND: Hemoglobin (Hb), white blood cell (WBC), and polymorphonuclear neutrophil (PMN) blood counts may be correlated with outcomes in patients with locally advanced cervical cancer. METHODS: Hb, WBC ... [more ▼]

BACKGROUND: Hemoglobin (Hb), white blood cell (WBC), and polymorphonuclear neutrophil (PMN) blood counts may be correlated with outcomes in patients with locally advanced cervical cancer. METHODS: Hb, WBC, and PMN counts were measured at diagnosis and during concomitant cisplatin-based chemoradiotherapy (CCRT) in a retrospective sample of 103 patients between 2010 and 2017. Red blood cell (RBC) transfusions were also recorded. The associations between hematological variables and patient overall survival (OS) and recurrence-free survival (RFS) were assessed by Cox regression models. RESULTS: The 3-year OS and RFS rates were 81.4% and 76.8%, respectively. In addition to tumor size and smoking, OS and RFS were found to be significantly associated with changes in WBC and PMN counts from the first to the last cisplatin cycle. Hb count throughout the treatment and RBC transfusions were not predictive of outcome. CONCLUSIONS: This study found no association between Hb count or RBC transfusions and outcome. The daily practice of maintaining the Hb count above 12 g/dL during CCRT should be weighed against the potential risks of transfusions. Drops in WBC and PMN counts during treatment positively impacted OS and RFS and could, therefore, serve as biomarkers during CCRT to adapt the follow-up and consider the need for adjuvant systemic treatments. [less ▲]

Detailed reference viewed: 46 (8 ULiège)
Full Text
Peer Reviewed
See detailTreatment algorithm in patients with ovarian cancer.
Vergote, I.; Denys, H.; De Greve, J. et al

in Facts, views & vision in ObGyn (2020), 12(3), 227-239

Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian ... [more ▼]

Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium. [less ▲]

Detailed reference viewed: 33 (4 ULiège)
Full Text
Peer Reviewed
See detailTisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong, David S.; Concin, Nicole; Vergote, Ignace et al

in Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

PURPOSE: Tissue factor (TF) is a potential target in cervical cancer as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody ... [more ▼]

PURPOSE: Tissue factor (TF) is a potential target in cervical cancer as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody-drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase 1/2 study (NCT02001623). EXPERIMENTAL DESIGN: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. RESULTS: Of the 55 patients, 51% had received >/=2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab+doublet chemotherapy. 51% of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% (95% confidence interval [CI]: 13%-37%). Median duration of response (DOR) was 4.2 months (range: 1.0+-9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%-43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%-35%), median DOR of 6.0 months (range: 1.0+-9.7), and 6-month PFS rate of 40% (95% CI: 24%-55%). TF expression was confirmed in most patients; no significant association with response was observed. CONCLUSIONS: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer. [less ▲]

Detailed reference viewed: 30 (4 ULiège)